Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of CJM112 in uncontrolled moderate to severe asthma
MOH_2018-02-27_002047Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing CJM112 with Placebo (2 arms). Started Feb 2018; status: completed.
02
Drugs
CJM112
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2018-02-27_002047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-27_002047.